Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values.

Dunlop W, Iqbal I, Khan I, Ouwens M, Heron L.

Clinicoecon Outcomes Res. 2013 Oct 30;5:555-64. doi: 10.2147/CEOR.S47867. eCollection 2013.

2.

Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis.

Buttgereit F, Kent JD, Holt RJ, Grahn AY, Rice P, Alten R, Yazici Y.

Bull Hosp Jt Dis (2013). 2015 Jul;73(3):168-77.

3.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

4.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

5.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

6.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

7.

Clinical effectiveness and cost-effectiveness results from the randomised controlled Trial of Oral Mandibular Advancement Devices for Obstructive sleep apnoea-hypopnoea (TOMADO) and long-term economic analysis of oral devices and continuous positive airway pressure.

Sharples L, Glover M, Clutterbuck-James A, Bennett M, Jordan J, Chadwick R, Pittman M, East C, Cameron M, Davies M, Oscroft N, Smith I, Morrell M, Fox-Rushby J, Quinnell T.

Health Technol Assess. 2014 Oct;18(67):1-296. doi: 10.3310/hta18670.

8.

Elicitation of health state utilities associated with differing durations of morning stiffness in rheumatoid arthritis.

Iqbal I, Dasgupta B, Taylor P, Heron L, Pilling C.

J Med Econ. 2012;15(6):1192-200. doi: 10.3111/13696998.2012.712927. Epub 2012 Aug 9.

PMID:
22804691
9.

Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.

Lee MY, Park SK, Park SY, Byun JH, Lee SM, Ko SK, Lee EK.

Clin Ther. 2015 Aug;37(8):1662-76.e2. doi: 10.1016/j.clinthera.2015.07.001. Epub 2015 Aug 1.

PMID:
26243076
10.

Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.

Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.

Pharmacoeconomics. 2012 Aug 1;30(8):e1-15. doi: 10.2165/11632920-000000000-00000.

11.

Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.

Sutcliffe P, Connock M, Pulikottil-Jacob R, Kandala NB, Suri G, Gurung T, Grove A, Shyangdan D, Briscoe S, Maheswaran H, Clarke A.

Health Technol Assess. 2013 Nov;17(53):1-499, v-vi. doi: 10.3310/hta17530. Review.

12.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

13.

Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.

Manning VL, Kaambwa B, Ratcliffe J, Scott DL, Choy E, Hurley MV, Bearne LM.

Rheumatology (Oxford). 2015 Feb;54(2):302-9. doi: 10.1093/rheumatology/keu319. Epub 2014 Aug 29.

PMID:
25173349
14.

Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.

Tikhonova IA, Hoyle MW, Snowsill TM, Cooper C, Varley-Campbell JL, Rudin CE, Mujica Mota RE.

Pharmacoeconomics. 2017 Mar;35(3):363-373. doi: 10.1007/s40273-016-0453-5. Review.

PMID:
27752999
15.

Modified-release prednisone: in patients with rheumatoid arthritis.

Henness S, Yang LP.

Drugs. 2013 Dec;73(18):2067-76. doi: 10.1007/s40265-013-0148-6. Review.

PMID:
24249648
16.
17.

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.

Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R.

Lancet. 2008 Jan 19;371(9608):205-14. doi: 10.1016/S0140-6736(08)60132-4.

PMID:
18207016
18.

Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.

Nazir J, Maman K, Neine ME, Briquet B, Odeyemi IA, Hakimi Z, Garnham A, Aballéa S.

Value Health. 2015 Sep;18(6):783-90. doi: 10.1016/j.jval.2015.05.011. Epub 2015 Sep 9.

19.
20.

Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation.

Clarke A, Pulikottil-Jacob R, Grove A, Freeman K, Mistry H, Tsertsvadze A, Connock M, Court R, Kandala NB, Costa M, Suri G, Metcalfe D, Crowther M, Morrow S, Johnson S, Sutcliffe P.

Health Technol Assess. 2015 Jan;19(10):1-668, vii-viii. doi: 10.3310/hta19100. Review.

Supplemental Content

Support Center